“Blood Screening market set to represent exceeding CAGR by 2029” says new Visiongain report

04 September 2019
Pharma

Visiongain has launched a new pharma report Blood Screening Market Forecast 2019-2029: By Technology (NAT, ELISA, CLIA, NGS, Western Blotting) & By Product (Reagents, Instruments) Segments.

The growth of the global blood screening market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Moreover, there is ever increasing demand for blood screening tests due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Also, governments across the countries are in process to mandates testing all donated blood for several viruses.

Blood donation requires the blood to be free from disease causing agents namely HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). This is done to decrease the chances of transfusion-transmitted contaminations (TTIs).

With continuous technological advancement in this segment, especially the U.S. FDA approved next-generation sequencing (NGS) technology in 2013 has made the blood screening cheaper and faster than previous DNA analysis methods has done well for the industry. The worldwide blood screening market is witnessing technological advancements with respect to devices and utilities involved in blood donation centres and doctor’s facilities for the screening of different TTIs.

Leading companies featured in the report include Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary Of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary Of Danaher Corporation), Becton, Dickinson And Company.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

 

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever